TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with Ukoniq (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 25, 2021 Category: Drugs & Pharmacology Source Type: news
IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Efficacy of BNT162b2 mRNA COVID-19 Vaccine Lower in Patients With CLL
THURSDAY, May 6, 2021 -- The BNT162b2 mRNA COVID-19 vaccine has lower efficacy among patients with chronic lymphocytic leukemia (CLL) and induces lower neutralizing antibody responses (NAbs) in elderly patients with multiple myeloma (MM) versus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2021 Category: Pharmaceuticals Source Type: news
Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Bas ed on this positive CHMP recommendation, a final decision regarding the approval of Venclyxto in certain patients with untreated AML is expected from the European Commission in the near future.“Today’s recommendation...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news
GENUINE Improvements: Ublituximab Plus Ibrutinib for CLL GENUINE Improvements: Ublituximab Plus Ibrutinib for CLL
Chronic lymphocytic leukemia (CLL) expert Jennifer R. Brown, MD, discusses the recently published GENUINE trial and its implications for treating high-risk patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 20, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Science Saturday: Regenerative eyedrops tap blood for tears
Gregory Williams turned to regenerative medicine for healing after a one-two punch to his health. The 63-year-old Florida man survived?leukemia?only to develop ocular?graft-versus-host?disease, a potentially blinding complication of the bone marrow transplant that put his cancer in remission. Ocular graft-versus-host disease is a chronic debilitating condition with no cure that causes severe dry eyes. The?Regenerative [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 17, 2021 Category: Databases & Libraries Source Type: news
An antibody-drug combo to combat cancer
(Tokyo Medical and Dental University) Researchers at Tokyo Medical and Dental University (TMDU) have developed an ingenious therapeutic strategy against chronic myelomonocytic leukemia that links a cytotoxic drug payload to an antibody vector that targets the CD64 marker highly expressed by monocytes and monocytic progenitors. This selective antibody-drug conjugate spares other blood cell lineages thus avoiding the side-effects of conventional anti-cancer drugs such as anemia, infection or bleeding diatheses. Consequently, this drug-delivery tactic shows great promise against other monocyte-related diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 16, 2021 Category: Cancer & Oncology Source Type: news
Studies suggest people with blood cancers may not be optimally protected after COVID-19 vaccination
(American Society of Hematology) Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer. According to researchers, these studies could help inform the ideal time for vaccination of these populations. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2021 Category: Infectious Diseases Source Type: news
EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma
The panel recommends EU approval for duvelisib (Copiktra) for certain patients with chronic lymphocytic leukemia (CLL) or follicular lymphoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with Ukoniq (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 29, 2021 Category: Drugs & Pharmacology Source Type: news
Oncotarget: Hispanic Chronic myelomonocytic leukemia patients
(Impact Journals LLC) This Oncotarget study had significantly lower mutation rates in ASXL1 and SETBP1, and a higher rate of muTET2/wtASXL1 (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 22, 2021 Category: International Medicine & Public Health Source Type: news
New BTK Inhibitor Pirtobrutinib Shows Promise in CLL New BTK Inhibitor Pirtobrutinib Shows Promise in CLL
The drug yielded promising outcomes in patients with chronic lymphocytic leukemia who discontinued BTK inhibitor treatment because of resistance or intolerance, according to results of the BRUIN trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
What Are the Stages of Chronic Lymphocytic Leukemia?
Title: What Are the Stages of Chronic Lymphocytic Leukemia?Category: Diseases and ConditionsCreated: 2/16/2021 12:00:00 AMLast Editorial Review: 2/16/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 16, 2021 Category: Cancer & Oncology Source Type: news
A potent weapon against lymphomas
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown inNature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news
Some English bulldogs thought to have cancer may have newly identified syndrome
(Morris Animal Foundation) Some English bulldogs diagnosed with a common cancer may instead have a newly described, non-cancerous syndrome called polyclonal B?cell lymphocytosis. The discovery was made by Morris Animal Foundation-funded researchers at Colorado State University during a study to better understand B-cell chronic lymphocytic leukemia (BCLL). The team published their findings in the Journal of Veterinary Internal Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news
